A preclinical study to investigate the development of nephrogenic systemic fibrosis: A possible role for gadolinium-based contrast media

Investigative Radiology

Volumn 43, Issue 1, 2008, Pages 65-75

  Sieber, Martin A ^a   Pietsch, Hubertus ^a   Walter, Jakob ^a   Haider, Wolfram ^b   Frenzel, Thomas ^a   Weinmann, Hanns Joachim ^a  

^a BAYER PHARMA AG   (Germany)

^b Institute of Animal Pathology   (Germany)

Author keywords

Contrast agent; Gadodiamide; Gadolinium; Gadopentetate dimeglumine; Magnetic resonance; Nephrogenic systemic fibrosis

Indexed keywords

CALDIAMIDE; CONTRAST MEDIUM; GADODIAMIDE; GADOLINIUM ETHYLENEDIAMINE TETRAACETIC ACID; GADOLINIUM PENTETATE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; ZINC;

ACANTHOSIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATOMIC EMISSION SPECTROMETRY; CELL INFILTRATION; CONTROLLED STUDY; DERMOEPIDERMAL CLEFT; EPIDERMIS; FEMUR; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; LIVER; MALE; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN; SKIN DISEASE; SKIN FIBROSIS; SKIN ULCER;

EID: 37549017297     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLI.0b013e31815e6277     Document Type: Article

References (55)

1. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356:1000-1001.
2. DeHoratius DM, Cowper SE. Nephrogenic systemic fibrosis: an emerging threat among renal patients. Semin Dial. 2006;19:191-194.
3. Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol. 2003;15:785-790.
4. Scheinfeld N. Nephrogenic fibrosing dermopathy: a comprehensive review for the dermatologist. Am J Clin Dermatol. 2006;7:237-247.
5. Cowper SE. Nephrogenic fibrosing dermopathy [NFD/NSF Website]. 2001-2007. Available at http://www.icnfdr.org.
6. Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol. 2003;25:358.
7. Kucher C, Xu X, Pasha T, et al. Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema. J Cutan Pathol. 2005;32:484-490.
8. Ortonne N, Lipsker D, Chantrel F, et al. Presence of CD45RO+ CD34+ cells with collagen synthesis activity in nephrogenic fibrosing dermopathy: a new pathogenic hypothesis. Br J Dermatol. 2004;150:1050-1052.
9. Edsall LC, English JC III, Teague MW, et al. Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy. J Cutan Pathol. 2004;31:247-253.
10. Lewis KG, Lester BW, Pan TD, et al. Nephrogenic fibrosing dermopathy and calciphylaxis with pseudoxanthoma elasticum-like changes. J Cutan Pathol. 2006;33:695-700.
11. Kuo PH, Kanal E, Abu-Alfa AK, et al. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology. 2007;242:647-649.
12. Piera-Velazquez S, Sandorfi N, Jimenez SA. Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy: clinical aspects. Skinmed. 2007;6:24-27.
13. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:3604-3605.
14. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359-2362.
15. FDA. http://www.fda.gov/cder/drug/infopage/gcca/.
16. Knopp MV, Balzer T, Esser M, et al. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use. Invest Radiol. 2006;41:491-499.
17. Bourrinet P, Martel E, El Amrani AI, et al. Cardiovascular safety of gadoterate meglumine (Gd-DOTA). Invest Radiol. 2007;42:63-77.
18. Herborn CU, Honold E, Wolf M, et al. Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Invest Radiol. 2007;42:58-62.
19. Caravan P, Ellison JJ, McMurry TJ, et al. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev. 1999;99:2293-2352.
20. Idee JM, Port M, Raynal I, et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol. 2006;20:563-576.
21. Schmitt-Willich H. Stability of linear and macrocyclic gadolinium based contrast agents. Br J Radiol. 2007;80:581-582; author reply 584-585.
22. Tweedle MF. "Stability" of gadolinium chelates. Br J Radiol. 2007;80:583-584; author reply 584-585.
23. Weinmann HJ, Brasch RC, Press WR, et al. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. AJR Am J Roentgenol. 1984;142:619-624.
24. Lauffer RB. Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design. Chem Rev. 1987;87:901-927.
25. Ide M, Kuwamura M, Kotani T, et al. Effects of gadolinium chloride (GdCl(3)) on the appearance of macrophage populations and fibrogenesis in thioacetamide-induced rat hepatic lesions. J Comp Pathol. 2005;133:92-102.
26. Oyaizu T, Okada Y, Shoji W, et al. Reduction of recipient macrophages by gadolinium chloride prevents development of obliterative airway disease in a rat model of heterotopic tracheal transplantation. Transplantation. 2003;76:1214-1220.
27. Spencer AJ, Wilson SA, Batchelor J, et al. Gadolinium chloride toxicity in the rat. Toxicol Pathol. 1997;25:245-255.
28. Kimura J, Ishiguchi T, Matsuda J, et al. Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents. Radiat Med. 2005;23:322-326.
29. Puttagunta NR, Gibby WA, Puttagunta VL. Comparative transmetallation kinetics and thermodynamic stability of gadolinium-DTPA bisglucosamide and other magnetic resonance imaging contrast media. Invest Radiol. 1996;31:619-624.
30. Puttagunta NR, Gibby WA, Smith GT. Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents. Invest Radiol. 1996;31:739-742.
31. Sarka L, Burai L, Brucher E. The rates of the exchange reactions between [Gd(DTPA)]2- and the endogenous ions Cu2+ and Zn2+: a kinetic model for the prediction of the in vivo stability of [Gd(DTPA)]2-, used as a contrast agent in magnetic resonance imaging. Chemistry. 2000;6:719-724.
32. Tweedle MF, Hagan JJ, Kumar K, et al. Reaction of gadolinium chelates with endogenously available ions. Magn Reson Imaging. 1991;9:409-415.
33. Saab G, Abu-Alfa A, Sadowski EA, et al. Are patients with moderate renal failure at risk for developing nephrogenic systemic fibrosis? Radiology. 2007;244:930-932.
34. Harpur ES, Worah D, Hals PA, et al. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest Radiol. 1993;28(Suppl 1):S28-S43.
35. Staks T, Schuhmann-Giampieri G, Frenzel T, et al. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest Radiol. 1994;29:709-715.
36. Weinmann HJ, Laniado M, Mutzel W. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR. 1984;16:167-172.
37. Jimenez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum. 2004;50:2660-2666.
38. VanWagoner M, O'Toole M, Worah D, et al. A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent. Invest Radiol. 1991;26:980-986.
39. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol. 1998;5:491-502.
40. Schuhmann-Giampieri G, Krestin G. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol. 1991;26:975-979.
41. Cacheris WP. Chelate Compositions. 1989.
42. Wedeking P, Kumar K, Tweedle MF. Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. Magn Reson Imaging. 1992;10:641-648.
43. Crissman JW, Goodman DG, Hildebrandt PK, et al. Best practices guideline: toxicologic histopathology. Toxicol Pathol. 2004;32:126-131.
44. Greaves P, ed. Integumentary System. Amsterdam: Elsevier; 2000:1-54.
45. Klein-Szanto A, Conti C. Skin and oral mucosa. In: Handbook of Toxicologic Pathology. Vol. 2. Haschek W, Rousseaux C, Wallig M, eds. San Diego: Academic Press; 2002:85-119.
46. Noelte J. ICP Emissionsspektometrie für Praktiker. Weinheim: Wiley-VCH Verlag GmbH; 2002.
47. Franzen C, Fischer S, Schroeder J, et al. In vitro cultivation of an insect microsporidian Tubulinosema ratisbonensis in mammalian cells. J Eukaryot Microbiol. 2005;52:349-355.
48. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243:148-157.
49. Quan TE, Cowper S, Wu SP, et al. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol. 2004;36:598-606.
50. Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging. 1990;8:467-481.
51. Khurana A, Runge VM, Narayanan M, et al. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan). Invest Radiol. 2007;42:139-145.
52. Habicht A, Watschinger B. [Sympathetic overactivity and the kidney.] Wien Klin Wochenschr. 2003;115:634-640.
53. Krinke G, Naylor DC, Skorpil V. Pyridoxine megavitaminosis: an analysis of the early changes induced with massive doses of vitamin B6 in rat primary sensory neurons. J Neuropathol Exp Neurol. 1985;44:117-129.
54. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol. 1995;30:372-380.
55. Sieber MA, Walter J, Frenzel T, et al. Are Gadolinium contrast agents a possible trigger for the development of nephrogenic fibrosing dermopathy? Eur Radiol. 2007;17(Suppl 1):158.